Video

Practical Management of Early Stage HER2+ Breast Cancer

Author(s):

Madelaine Kuiper, NP, UCLA Santa Monica Hematology/OncologyLoyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

Nurse practitioners provide insight on issues surrounding the administration of dual HER2-targeted therapy in the neoadjuvant/adjuvant setting and counseling patients on common AEs associated with trastuzumab-pertuzumab for the treatment of HER2+ breast cancer.

Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Yuan Yuan, MD, PhD
Paolo Tarantino, MD
Yuan Yuan, MD, PhD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Yuan Yuan, MD, PhD
Related Content
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
September 17th 2024

FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Peter A. Fasching, MD
September 16th 2024

Adjuvant Ribociclib Sustains DFS, DDFS Benefit in HR+/HER2– Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Peter Schmid, MD, PhD, Barts College
September 15th 2024

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC

Oleg Gluz, MD
September 14th 2024

Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer